Edition:
India

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

13.40USD
16 Aug 2019
Change (% chg)

$0.93 (+7.46%)
Prev Close
$12.47
Open
$12.52
Day's High
$13.42
Day's Low
$12.48
Volume
377,089
Avg. Vol
243,191
52-wk High
$16.38
52-wk Low
$2.62

Summary

Name Age Since Current Position

Patrick Machado

54 2019 Chairman of the Board

Leone Patterson

55 2018 President, Chief Executive Officer

Thomas Leung

38 2019 Chief Financial Officer

Mehdi Gasmi

51 2017 Chief Science and Technology Officer

Jennifer Cheng

45 2017 Vice President, General Counsel

Mike Fitzgerald

58 2018 Vice President of Human Resources

Aaron Osborne

2019 Chief Medical Officer

Mitchell Finer

59 2016 Director

Rekha Hemrajani

49 2019 Director

Lawrence Kam

2019 Director

Mark Lupher

2019 Director

James Scopa

2019 Director

Eric Carter

65 2017 Independent Director

Richard Spivey

68 2017 Independent Director

Thomas Woiwode

46 2016 Independent Director

Biographies

Name Description

Patrick Machado

Mr. Patrick Machado J.D is Chairman of the Board of the company. he was Independent Director of the Company.Mr. Machado was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its Chief Business Officer from 2009 to 2014 and as its Chief Financial Officer from 2004 until his retirement in 2014. From 1998 to 2001, Mr. Machado worked with ProDuct Health, Inc., a medical device company, as Senior Vice President, Chief Financial Officer and earlier as General Counsel. Upon ProDuct Health’s acquisition by Cytyc Corporation, a diagnostic and medical device company, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado also serves as a member of the board of directors of Endocyte, Inc., Chimerix, Inc. and SCYNEXIS, Inc., and previously served on the board of directors of Inotek Pharmaceuticals Corporation, Axovant Sciences, Inc. and Medivation, Inc. Mr. Machado received a B.A. in German and a B.S. in Economics from Santa Clara University and a J.D. from Harvard Law School. Mr. Machado has been chosen to serve on our Board due to his extensive experience dealing with the operational and financial issues of biopharmaceutical companies

Leone Patterson

Ms. Leone D. Patterson serves as President and Chief Executive Officer, Chief Financial Officer of the Company. Ms. Patterson has served as Adverum’s Chief Financial Officer since June 2016 and as Adverum’s Senior Vice President since February 2018. From March 2015 to June 2016, Ms. Patterson served as the Chief Financial Officer of Diadexus, Inc., a diagnostics company, where she was responsible for overseeing the company’s finance function. Prior to that, Ms. Patterson was Vice President and Chief Financial Officer of Transcept Pharmaceuticals, Inc., a biopharmaceutical company, from June 2012 until it was acquired by Paratek Pharmaceuticals Inc. in October 2014, where she was responsible for overseeing the company’s finance function. From November 2010 to June 2012, Ms. Patterson served as Vice President and Global Corporate Controller of NetApp, Inc., a data management and storage company. From July 2007 to November 2010, Ms. Patterson was Vice President of Finance at Exelixis, Inc, a biopharmaceutical company. Before Exelixis, Ms. Patterson served as Vice President of Global Business Planning and Analysis of the Vaccines and Diagnostics Division of Novartis AG, a biopharmaceutical company, from April 2006 to July 2007. From 1999 to 2006, she held several positions, including Vice President, Corporate Controller, at Chiron, a biotechnology company (now part of Novartis AG). From 1989 to 1999, Ms. Patterson worked in the audit practice of accounting firm KPMG, where she held various positions including Senior Manager. Ms. Patterson earned a B.S. in business administration and accounting from Chapman University and an executive M.B.A. from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).

Thomas Leung

Mr. Thomas Leung is Chief Financial Officer of the Company. He most recently served as vice president, business operations at Counsyl, Inc., a genetic screening company acquired by Myriad Genetics, Inc., where he held leadership roles in finance, strategy, billing operations and sales operations from August 2013 to April 2019. Prior to Counsyl, Mr. Leung served as a Vice President of TPG Capital in San Francisco and Hong Kong, where he was responsible for sourcing investments, executing acquisitions and financings and managing portfolio companies. Mr. Leung began his career in investment banking at Morgan Stanley & Co. He holds an M.B.A. from Harvard Business School and received a B.S. in economics and biomedical engineering from Yale University.

Mehdi Gasmi

Dr. Mehdi Gasmi, Ph.D. is Chief Science and Technology Officer of the Company. Dr. Gasmi has served as Senior Vice President, Pharmaceutical Development of the Company since June 2015 and Vice President, Pharmaceutical Development of the Company from November 2013 to June 2015. Dr. Gasmi leads manufacturing and quality control efforts for the Company’s gene therapy product candidates. From December 2011 to November 2013, as principal of ClinVec Solutions, LLC, Dr. Gasmi provided adeno-associated virus (AAV) and lentiviral gene therapy consulting services to various companies, including to the Company between June 2013 to October 2013. Prior to that, Dr. Gasmi oversaw production of clinical batches of recombinant AAV and lentiviral gene therapy products for both Généthon, a gene therapy company, where he served as Vice President of Biomanufacturing from July 2009 to December 2011, and for Ceregene, a gene therapy company, where Dr. Gasmi served as Senior Director, Product Development from December 2001 to June 2009. Dr. Gasmi obtained his M.S. and his Ph.D. in Biochemistry from the Claude Bernard University in Lyon, France. He is a member of the American Society of Gene and Cell Therapy.

Jennifer Cheng

Dr. Jennifer Cheng, J.D., Ph.D. is Vice President, General Counsel of the Company. Dr. Cheng has served as our Vice President and General Counsel since February 2017. Previously, she served as our Vice President and Associate General Counsel from February 2016 to February 2018, and as Senior Patent Counsel, Director of Intellectual Property from June 2015 to February 2016. Prior to joining Adverum, she served as a patent counsel at Allergan from March 2013 to May 2015, where she was responsible for the prosecution and maintenance of the company’s patent portfolio directed to certain technologies, research and development programs and certain products and product candidates, and as the senior patent counsel at MAP Pharmaceuticals, a biotechnology company, from June 2011 until its acquisition by Allergan in March 2013. From August 2008 to May 2011, Dr. Cheng served as the manager of intellectual property at Solazyme, Inc., a biotechnology company, and previously was a patent counsel at Raven Biotechnologies, Inc., a biotechnology company. Dr. Cheng received a B.A. from the University of California at Berkeley, a Ph.D. in tumor cell biology and molecular medicine from Northwestern University and a J.D. from Santa Clara University School of Law.

Mike Fitzgerald

Mr. Mike Fitzgerald is Vice President of Human Resources of the company. Mr. Fitzgerald has over 23 years of experience leading successful and effective teams. Prior to joining Adverum, Mr. Fitzgerald was the Senior Vice President, Global Human Resources for ZELTIQ Aesthetics (now Allergan). Prior to ZELTIQ, he served as the Executive Vice President, Global Human Resources for Cepheid, a leading company in molecular diagnostics, where he was responsible for devising and implementing the company's human capital strategy and associated programs. Before joining Cepheid, he served as the Senior Vice President of Global Human Resources at Verigy, Ltd (now a part of Advantest Corp.). Prior to Verigy, Mr. Fitzgerald was Vice President of Human Resources at Varian, Inc. (acquired by Agilent Technologies), and prior to that, he held various HR roles culminating in becoming the Global Director of HR Strategy and Planning for Vodafone Group, plc.

Aaron Osborne

Dr. Aaron Osborne is Chief Medical Officer of the company. Dr. Osborne has over twelve years of experience in the biopharmaceutical industry together with five years of clinical practice in the British National Health Service (NHS) as an ophthalmologist. He brings significant expertise in clinical development and broad relationships across the ophthalmic community. Dr. Osborne joins Adverum from Genentech, where he served as principal medical director in product development and global development leader for faricimab, guiding the design and execution of Phase II and Phase III studies in wet age-related macular degeneration (AMD) and diabetic macular edema (DME), respectively. Previously, Dr. Osborne served as global medical affairs pharmaceuticals franchise head at Alcon. He served as head of global medical affairs for ophthalmic programs at Novartis, where he led the medical oversight of Lucentis' late-stage development and post-marketing studies, achieving worldwide regulatory approvals and patient access in wet AMD, DME, retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). Dr. Osborne trained in ophthalmology at Queens Medical Centre, Nottingham, and earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree at University College London.

Mitchell Finer

Mr. Mitchell H. Finer, Ph.D., is Director of the Company.Dr. Finer has served as a managing director of MPM Capital, a venture capital firm, since September 2015. Dr. Finer is a founder of Adverum, and previously served as one of our distinguished research fellows. Since April 2015, Mr. Finer has served as Chief Executive Officer and Chief Scientific Officer of Oncorus, Inc., a biotechnology company. Since April 2017, Mr. Finer has also served as interim Chief Executive Officer of CODA Biotherapeutics, Inc., a biopharmaceutical company. Previously, he served as Chief Scientific Officer of bluebird bio, Inc. (“bluebird”), a biopharmaceutical company, from March 2010 through July 2015. Prior to joining bluebird, Dr. Finer served as senior vice president of development and operations for Novocell, Inc. (now part of ViaCyte, Inc.), a stem cell engineering company, from November 2008 through March 2010. From July 2005 through November 2008, Dr. Finer served as Chief Executive Officer of Intracel Holdings LLC. He was also a founder and Vice President of Research for Cell Genesys Inc., and a founder of Abgenix, Inc. Dr. Finer received a B.A. in biochemistry and bacteriology from the University of California, Berkeley and a Ph.D. in biochemistry and molecular biology from Harvard University. He completed a postdoctoral fellowship at the Whitehead Institute for Biomedical Research. Dr. Finer has been chosen to serve on our Board due to his operational, strategic and corporate leadership experience and his experience as a founder of numerous biopharmaceutical companies

Rekha Hemrajani

Ms. Rekha Hemrajani is Director of the company. Rekha Hemrajani, M.B.A. has more than 20 years of biopharmaceutical industry experience and has extensive expertise in all aspects of corporate and business development, financing, and strategic planning. Ms. Hemrajani serves as chief financial officer and chief operating officer of Arcus Biosciences, Inc. where she leads finance, investor relations, corporate communications, business and corporate development, strategic planning, and human resources. Previously, she was chief operating officer for FLX Bio, chief financial officer and senior vice president of business and financial operations at 3-V Biosciences, vice president, head of licensing and mergers and acquisitions at Onyx Pharmaceuticals, Inc., and vice president of business development at Exelixis, Inc. Ms. Hemrajani began her career in investment banking at Credit Suisse and Lehman Brothers. Ms. Hemrajani earned a B.S. in economics and computer science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.

Lawrence Kam

Mark Lupher

Dr. Mark Lupher Jr. Ph.D. is Director of the company. Mark Lupher, Ph.D. is a biopharmaceutical executive with over 28 years of experience with biomedical research organizations and over 12 years of experience serving in various executive level roles. He currently serves as the Vice President of translational pharmacology and preclinical development at Sutro Biopharma, a biotechnology company focused on clinical-stage drug discovery, development and manufacturing. Dr. Lupher also currently serves as the President and Founder of VeritasRx Consulting, an executive consulting service he founded in 2013. Previously, Dr. Lupher held a variety of executive roles at biopharmaceutical companies, including serving as Chief Scientific Officer at Promedior, Inc. `. Lupher received a Ph.D. in immunology from Harvard University and a B.S. in microbiology from the University of Washington.

James Scopa

Mr. James Scopa is Director of the company. James Scopa, J.D., M.B.A. brings over 30 years of experience in the life sciences industry, investing in companies and advising public and private boards on strategic and financial transactions. He most recently was a Managing Director and Member of the Investment Committee of MPM Capital, a global life sciences venture capital firm. Prior to MPM, Mr. Scopa spent 18 years advising growth companies in biopharmaceuticals and medical devices principally at Deutsche Banc Alex Brown and Thomas Weisel Partners. Mr. Scopa currently serves on the Board of Directors of Blade Therapeutics as Chair of its Audit Committee and on its Compensation Committee, as well as the Advisory Board and the Investment Advisory Committee of One Ventures. Mr. Scopa received an A.B. from Harvard College, an M.B.A. from Harvard Business School and a J.D. from Harvard Law School.

Eric Carter

Dr. Eric G. Carter M.D., Ph.D. is Director of the company. He is a pharmaceutical industry executive with over 20 years of global research and development experience in multiple therapeutic areas. Most recently, Dr. Carter served as senior vice president, chief medical officer, and global head of clinical and non-clinical development of Allergan, plc, a pharmaceutical company, from 2011 through a period of significant growth until its acquisition by Actavis Pharmaceuticals in 2015. Prior to Allergan, Dr. Carter served as chief scientific officer, head of research and development, and chief medical officer of King Pharmaceuticals from 2007 until the company was acquired by Pfizer, Inc. in 2011. From 2001 to 2007, he worked for GlaxoSmithKline plc, a pharmaceutical company, in positions of increasing responsibility within the global clinical development and medical affairs areas. After serving in academia at the University of North Carolina School of Medicine, the UCLA Fielding School of Public Health, and the University of California, Berkeley, Dr. Carter began his pharmaceutical career at Pharmacia Corporation, a pharmaceutical company, in 1993. He received a B.Sc. in Biochemistry from the University of London, a Ph.D. in Biochemistry from the University of Cambridge, and an M.D. from the University of Miami School of Medicine. Dr. Carter currently serves as the chair of the scientific advisory board at Bioniz Therapeutics. Dr. Carter has been chosen to serve on our Board due to his significant global experience in research and development in multiple therapeutic areas.

Richard Spivey

Dr. Richard N. Spivey is Independent Director of the company. Dr. Spivey has over 30 years of experience in research and development at leading global pharmaceutical companies. Dr. Spivey currently serves as a scientific advisor to the pharmaceutical industry. From 2010 to 2015, Dr. Spivey served as Senior Vice President of Global Regulatory Affairs at Allergan. From 2002 to 2010, Dr. Spivey worked with Meda AB, a pharmaceutical company, after its acquisition of MedPointe Pharmaceuticals, serving as Chief Scientific Officer and head of research and development for both. Earlier in his career, Dr. Spivey worked for pharmaceutical companies Pharmacia Corporation (now part of Pfizer), Schering-Plough Corporation (now part of Merck & Co.), Parke-Davis/Warner-Lambert (now part of Pfizer), and Boots Pharmaceuticals, Inc. Dr. Spivey previously served on the board of directors of Inotek Pharmaceuticals Corporation. Dr. Spivey received a Ph.D. in Pharmacy Administration from the University of Minnesota and a Pharm.D. from the University of Southern California. Dr. Spivey has been chosen to serve on our Board due to his extensive and distinguished experience in drug development and regulatory affairs.

Thomas Woiwode

Mr. Thomas Woiwode, Ph.D., is Independent Director of the Company.Dr. Woiwode has been with Versant Ventures, a venture capital firm, since 2002 in various capacities, serving as a Venture Partner since 2011 and a Managing Director since 2014. He has served in a number of operating roles over this time, most recently as the chief operating officer of Okairos AG, a biopharmaceutical company, from April 2011 until May 2013, when Okairos was sold to GlaxoSmithKline plc. Prior to Okairos, Dr. Woiwode co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding chief business officer for three biotech companies created within Versant. Dr. Woiwode was a research scientist at XenoPort, Inc., a biotechnology company, before joining Versant. Dr. Woiwode serves on the board of directors of CRISPR Therapeutics AG and previously served on the board of directors of Audentes Therapeutics, Inc. He received a B.A. in English and a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in organic chemistry from Stanford University. Dr. Woiwode has been chosen to serve on our Board due to his educational background, his experience as a board member and senior executive of biotechnology and pharmaceutical companies, and his experience as an investor in new life sciences companies